Objective: To develop a
HPLC-ESI-MS assay for rapidly determinating
telmisartan in human
plasma and to evaluate the
pharmacokinetics and bioequivalence of two telmisartan
tablets in human. Methods: After being deproteined by acetonitril, plasma samples were separated by HPLC-ESI-MS on a reversed-phase C 18 column with a mobile phase of 10 mmol/L ammonium acetate buffer solution (pH 3.5)-methanol (9∶91,V/V) and a fragmentor voltage of 120 V, in which the target ions (m/z) were at 515.5 for telmisartan and 423.4 for the internal standard. The randomized crossover trial was performed in 20 healthy volunteers using the test tablets and reference tablets individually at a single 40 mg dose. Then blood samplings from the subjects were conducted for HPLC-ESI-MS
analysis and the main pharmacokinetic parameters were determined thereby. Results: Calibration curve obtained was linear over the range of 0.3012～602.4 μg/L. Determination of a blood sample by this method was completed within 3.5 min. t 1/2, T
max and C max were (24.7±4.2) h, (1.8±0.5) h and (219.2±119.0) μg/L for the reference tablets and (23.3±5.6) h, (1.7±0.7) h and (209.8±125.9) μg/L for the test tablets, individually. The relative bioavalability of the test tablets was (100.5±8.3)%. The results of variance analysis and two one-sided t-test showed that there was no significant difference between the two preparations in the AUC and C max. Conclusion: The assay was proved to be rapid, sensitive, accurate and convenient. The two preparations were bioequivalent.
More abstracts about the Rapid Determination of Telmisartan in Human Plasma and Study of Bioequivalence of Its Tablets in Hea